U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180082) titled 'Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer' on Sept. 11.
Brief Summary: This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Breast Cancer
Intervention:
DRUG: Pyrotinib
anti-HER2 tyrosine kinase inhibitor
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Wenjin Yin
Information provided by (Responsible Party): Wenjin Yin, ...